Kezar Life Sciences Inc — Cash Flow (NASDAQ:KZR) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -36.95 M-42.44 M-58.85 M-81.64 M-74.21 M-51.78 M -51.78 M Cash from investing activities -56.5 M-28.44 M-91.39 M76.05 M80.43 M92.46 M 92.46 M Cash from financing activities 99.64 M112.58 M127.86 M638 K103 K-10.59 M -10.59 M Free cash flow -37.14 M-42.75 M-60.42 M-83.45 M-74.24 M-51.78 M -51.78 M

뉴스

Enodia acquires Kezar’s Sec61 program assets for $127M potential

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

케자르, 구조조정 일환으로 인력 감축 발표

Kezar Life Sciences announces workforce reduction as part of restructuring

케자르 AIH 치료제, 스테로이드 감소 효과

Kezar’s AIH drug shows promise in steroid reduction, trial data reveals

키자 라이프 사이언스, 630만 달러 대출 상환 및 Oxford Finance와 계약 종료

Kezar Life Sciences repays $6.3 million loan and ends agreement with Oxford Finance

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.52%

Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR)

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Booz Allen Hamilton (NYSE:BAH), AST SpaceMobile (NASDAQ:ASTS)

윌리엄 블레어, 키자 라이프 사이언스 투자의견 강등: FDA 차질